Event Timeline
| 08:00 AM - 08:05 AM |
|
Introduction
Stefan M. Pulst, MD, FAAN
|
| 08:00 AM - 05:00 PM |
Abstract |
001 - Transplantation of LeX+/CXCR4+ Adult Neural Stem Cells in the Spinal Cord of a Murine Model of Amyotrophic Lateral Sclerosis
|
| 08:00 AM - 05:00 PM |
Abstract |
001 - MEF2 as an Anti-Apoptotic, Neurogenic Transcription Factor in Murine ES Cells: Beneficial Effect of Transplantation after Middle Cerebral Artery Stroke in Mice
|
| 08:00 AM - 05:00 PM |
Abstract |
002 - The Histone Deacetylase Inhibitors Valproic Acid and Sodium Butryate Ameliorate Expanded CAG Repeat Toxicity Observed in Embryonic Stem Cell Models of Huntington's Disease and Polyglutamine Disorders
|
| 08:00 AM - 05:00 PM |
Abstract |
002 - Safety and Feasibility of Intra-Arterial Autologous Bone Marrow Mononuclear Cells Transplantation in Acute Ischemic Stroke
|
| 08:00 AM - 05:00 PM |
Abstract |
003 - Rapid Generation of Homogenous Neural Precursors from Human Embryonic Stem Cells
|
| 08:00 AM - 05:00 PM |
Abstract |
003 - Transplantation of Bone Marrow-Derived Multipotent Progenitor Cells in Adult and Neonatal Models of Ischemic Injury
|
| 08:00 AM - 05:00 PM |
Abstract |
004 - N-CoR Pathway Targeting Induces Brain Tumor Stem Cell Differentiation
|
| 08:00 AM - 05:00 PM |
Abstract |
004 - Value of Electroencephalography and Transcranial Doppler Monitoring during Autologous Bone Marrow Mononuclear Cells Transplantation in Acute Ischemic Stroke
|
| 08:00 AM - 05:00 PM |
Abstract |
005 - Alginate-Based Anisotropic Capillary Hydrogels Promote Oriented Axonal Regrowth in the Injured Spinal Cord
|
| 08:00 AM - 05:00 PM |
Abstract |
006 - Cell Transplantation Impairs Structural and Functional Recovery Following Acute Contusion Spinal Cord Injury in Adult Rats
|
| 08:00 AM - 05:00 PM |
Abstract |
007 - SOX2-Dependent Dedifferentiation of Human Astrocytes in Multipotent Stem Cells as Possible Cell Source for Repair in CNS Diseases
|
| 08:00 AM - 05:00 PM |
Abstract |
008 - Transforming Growth Factor-beta1 Is a Negative Modulator of Adult Neurogenesis
|
| 08:00 AM - 05:00 PM |
Abstract |
009 - Investigating the Cancer Stem Cell Hypothesis in Human Glioblastomas: Co-Localization of ATF5 and CD133 Identifies a Subpopulation of Progenitor-Like Cells
|
| 08:00 AM - 05:00 PM |
Abstract |
010 - Developmentally-Arrested Multipotent Mesodermal Cells in von Hippel-Lindau Disease Associated Hemangioblastomas: Identification of Hemangioblasts
|
| 08:00 AM - 05:00 PM |
Abstract |
011 - Therapeutic Study of the Transplantation Human Embryonic Midbrain Neural Stem Cells into the Rhesus Models of Pakinson's Disease
|
| 08:00 AM - 05:00 PM |
Abstract |
012 - Hematopoietic Stem Cell Mobilization Therapy for Multiple Sclerosis: Method and Toxicity
|
| 08:00 AM - 05:00 PM |
Abstract |
013 - Immunoablation and Autologous Hematopoietic Stem Cell Transplantation May Enhance Remyelination in Acute Multiple Sclerosis Lesions
|
| 08:00 AM - 05:00 PM |
Abstract |
014 - Myogenic Differentiation of Murine Embryonic Stem Cells (MESC)
|
| 08:05 AM - 08:35 AM |
|
Setting the Stage: Overview and Normal Adult Neurogenesis
Fred H. Gage, PhD
|
| 08:35 AM - 08:40 AM |
|
Introduction
Stefan M. Pulst, MD, FAAN
|
| 08:40 AM - 09:05 AM |
|
Ethics, Politics, and Stem Cells
Laurie Zoloth, PhD
|
| 09:05 AM - 09:25 AM |
|
Panel Discussion
David Hess, MD
|
| 09:25 AM - 09:30 AM |
|
Introduction
Raymond P. Roos, MD, FAAN
|
| 09:30 AM - 09:55 AM |
|
Stem Cells and Motor Neurons
Samuel Pfaff, MD
|
| 09:55 AM - 10:20 AM |
|
Stem Cells, Motor Neuron Disease and Spinal Cord Injury
Clive Svendsen, PhD
|
| 10:20 AM - 10:35 AM |
|
Abstract (Dr. Corti)
|
| 10:35 AM - 11:05 AM |
|
Break
|
| 11:05 AM - 11:10 AM |
|
Introduction
John W. Griffin, MD
|
| 11:10 AM - 11:40 AM |
|
Stem Cells, Dopaminergic Cells, and Parkinson's Disease
Ole Isacson, MD
|
| 11:40 AM - 11:55 AM |
|
Abstract (Dr. Lorincz)
|
| 12:10 PM - 01:30 PM |
|
Lunch
|
| 01:30 PM - 01:35 PM |
|
Introduction
Brenda L. Banwell, MD, FAAN
|
| 01:35 PM - 02:00 PM |
|
Multiple Sclerosis
Steven A. Goldman, MD, PhD
|
| 02:00 PM - 02:25 PM |
|
Oligodendrocytes
Hans Keirstead, PhD
|
| 02:25 PM - 02:40 PM |
|
Abstract (Dr. Bajpai)
|
| 02:40 PM - 03:15 PM |
|
Break
|
| 03:15 PM - 03:45 PM |
|
Stem Cells and Brain Tumors
Xandra O. Breakefield, PhD
|
| 03:45 PM - 04:00 PM |
|
Abstract (Dr. Park)
|
| 04:00 PM - 04:30 PM |
|
The California Institute for Regenerative Medicine: The Future of Stem Cell Research in California and Elsewhere
Zach W. Hall, PhD
|
| 04:30 PM - 05:00 PM |
|
Scientific Aspects of Stem Cells in Neurological Disease
|
Faculty Disclosures
|
No disclosure on file
|
| Roger L. Albin, MD |
Dr. Albin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Albin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Albin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Albin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaccinex. The institution of Dr. Albin has received research support from NIH-NINDS. The institution of Dr. Albin has received research support from Parkinson's Foundation. The institution of Dr. Albin has received research support from Michael J. Fox Foundation. Dr. Albin has received personal compensation in the range of $5,000-$9,999 for serving as a Grant Application Reivewer with Michael J. Fox Foundation. |
| Douglas L. Arnold, MD, FAAN |
Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has stock in NeuroRx. |
| Nereo Bresolin, DR |
No disclosure on file
|
| James E. Carroll, MD, FAAN |
No disclosure on file
|
| Mark S. Freedman, MD, FAAN |
Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme. |
| Steven A. Goldman, MD, PhD |
No disclosure on file
|
| John W. Griffin, MD |
No disclosure on file
|
| George Karpati, MD |
No disclosure on file
|
| Stuart A. Lipton, MD, PhD, FAAN |
Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Deerfield Management. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Panorama Research, Inc.. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Circumvent Therapeutics, Inc.. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Harvard Medical School/Boston Children's Hostpial. Dr. Lipton has stock in EuMentis Therapeutics, Inc.. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from CIRM California Institute for Regenerative Medicine. The institution of Dr. Lipton has received research support from TRDRP California Tobacco Related Research/UCOP. The institution of Dr. Lipton has received research support from Circumvent Pharmaceuticals. Dr. Lipton has received intellectual property interests from a discovery or technology relating to health care. Dr. Lipton has received intellectual property interests from a discovery or technology relating to health care. Dr. Lipton has received intellectual property interests from a discovery or technology relating to health care. Dr. Lipton has received intellectual property interests from a discovery or technology relating to health care. Dr. Lipton has a non-compensated relationship as a Associate Editor with Neuron (Cell Press) that is relevant to AAN interests or activities. |
| Stefan M. Pulst, MD, FAAN |
Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care. |
| Raymond P. Roos, MD, FAAN |
Dr. Roos has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink. Dr. Roos has stock in Amazon. Dr. Roos has stock in Amgen. Dr. Roos has stock in Apple. Dr. Roos has stock in Cigna. Dr. Roos has stock in IBM. Dr. Roos has stock in Ionis. Dr. Roos has stock in Pfizer. Dr. Roos has received research support from Lohengrin Foundation. |
| Michael A. Williams, MD, FAAN |
Dr. Williams has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for the Hydrocephalus Association, a not-for-profit patient advocacay organization. The institution of Dr. Williams has received research support from NASA. The institution of Dr. Williams has received research support from Translational Research Insitute for Space Health (TRISH). The institution of Dr. Williams has received research support from NINDS. |
| Paulo R. Bittencourt, MD, PhD |
No disclosure on file
|
| David Hess, MD |
No disclosure on file
|
| Xandra O. Breakefield, PhD |
Dr. Breakefield has nothing to disclose. |
| Randolph S. Marshall, MD, FAAN |
The institution of Dr. Marshall has received research support from NIH. Dr. Marshall has received publishing royalties from a publication relating to health care. |
| Ulrich Bogdahn, MD |
No disclosure on file
|
| Shinji Ohara, MD, FAAN |
No disclosure on file
|
| Juergen Winkler |
No disclosure on file
|
| Emily Stern, MD |
No disclosure on file
|
| Brenda L. Banwell, MD, FAAN |
Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH. |
| Zach W. Hall, PhD |
No disclosure on file
|
| Fred H. Gage, PhD |
No disclosure on file
|
| Ping Zhuang, PhD |
Dr. Zhuang has nothing to disclose. |
| Philippe Ryvlin, MD, PhD |
Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle/Angelini. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini pharma. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB pharma. The institution of Dr. Ryvlin has received research support from Swiss National Fund. The institution of Dr. Ryvlin has received research support from European Commission (Horizon Europe). |
| Deric M. Park, MD |
No disclosure on file
|
| Gabriel R. De Freitas, MD, PhD |
Dr. De Freitas has nothing to disclose. |
| Ole Isacson, MD |
No disclosure on file
|
| Gary Tong, MD, PhD |
No disclosure on file
|
| Matthew T. Lorincz, MD, PhD |
Dr. Lorincz has received personal compensation for serving as an employee of Alexion. Dr. Lorincz has received personal compensation for serving as an employee of Orphalon . Dr. Lorincz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Lorincz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orphalon . Dr. Lorincz has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink Neurology. The institution of Dr. Lorincz has received research support from Alexion. |
| Maria L. Mendonca, MD |
No disclosure on file
|
| Jaderson C. Da Costa, PhD |
No disclosure on file
|
| Stefania Corti, MD, PhD |
Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Corti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. |
| Yoshiaki Furukawa, MD |
No disclosure on file
|
| Sridar Narayanan |
Sridar Narayanan has received personal compensation for serving as an employee of NeuroRx Research. Sridar Narayanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech Inc.. The institution of Sridar Narayanan has received research support from Immunotec Inc. |
| Marcus Kaul |
No disclosure on file
|
| Josephine Nalbantoglu |
No disclosure on file
|
| Arsen Aslanyan, MD |
No disclosure on file
|
| Charles Andre, MD |
No disclosure on file
|
| Daniel D. Bezerra, MD |
No disclosure on file
|
| Jacqueline Chen |
No disclosure on file
|
| Roberto Del Bo, PhD |
No disclosure on file
|
| Dimitra Papadimitriou, DO |
No disclosure on file
|
| Federica Locatelli, DO |
No disclosure on file
|
| Cesar Borlongan |
No disclosure on file
|
| Cheng-Chuan Jiang, MD |
No disclosure on file
|
| Noriyuki Matsukawa, MD, PhD |
No disclosure on file
|
| Joyce H. Ma |
No disclosure on file
|
| Ludwig Aigner, PhD |
No disclosure on file
|
| Ling L. Chen, PhD |
No disclosure on file
|
| Norbert Weidner, MD |
No disclosure on file
|
| Chai Tian, PhD |
No disclosure on file
|
| Beate Winner, MD |
No disclosure on file
|
| Ruchi Bajpai |
No disclosure on file
|
| Daniel Santos |
No disclosure on file
|
| Laurie Zoloth, PhD |
No disclosure on file
|
| Samuel Pfaff, MD |
No disclosure on file
|
| Clive Svendsen, PhD |
No disclosure on file
|
| Hans Keirstead, PhD |
Dr. Keirstead has received personal compensation for serving as an employee of AIVITA Biomedical. Dr. Keirstead has received personal compensation for serving as an employee of Human Immunome Project. Dr. Keirstead has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Immunis . Dr. Keirstead has stock in AIVITA Biomedical. Dr. Keirstead has stock in Immunis. Dr. Keirstead has received intellectual property interests from a discovery or technology relating to health care. |
| Sebastian Fridman, MD |
Dr. Fridman has nothing to disclose. |
| Subhash Tummala, MD |
No disclosure on file
|
| Benjamin H. Fuchs, MD |
Dr. Fuchs has nothing to disclose. |
| Laura Gaetano |
Laura Gaetano has received personal compensation for serving as an employee of Roche. Laura Gaetano has received stock or an ownership interest from Roche. |
| Rosanne Govaarts, MSc |
Ms. Govaarts has nothing to disclose. |
| Yo-ichi Takei |
No disclosure on file
|
| Stephanie Manberg, DO |
The institution of Dr. Manberg has received research support from AMO. |
| Alison Headley, MD |
No disclosure on file
|
| Anson Wang, MD |
Dr. Wang has nothing to disclose. |
| Steven H. Lang |
Mr. Lang has nothing to disclose. |
| Benjamin Chipper Doudican |
Mr. Doudican has nothing to disclose. |
| Connie Wolford, NP |
Ms. Wolford has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. |
| Ryan Hebert |
Ryan Hebert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus . |